By Sean Zheng
Key messages
- Heart failure with preserved ejection fraction (HFPEF) is a common cause of hospitalisation, impaired quality of life, restricted functional capacity, and mortality. There are currently no specific treatments for HFPEF with proven efficacy.
- PARAGON-HF (sacubitril-valsartan) demonstrated statistically non-significant improvements in heart failure outcomes in HFPEF, most notably signs of greater efficacy in those participants with lower left ventricular ejection fractions.
- Ongoing studies (DELIVER and EMPEROR-Preserved) will evaluate the effects of SGLT-2 inhibitors, a class of agent with striking efficacy in heart failure with reduced ejection fraction, in HFPEF.
